Infect Chemother . Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication

[tetano]

Infect Chemother


. 2020 Jul 16.
Online ahead of print.
Early Hydroxychloroquine Administration for Rapid Severe Acute Respiratory Syndrome Coronavirus 2 Eradication


Kyung Soo Hong[SUP] 1 [/SUP], Jong Geol Jang[SUP] 1 [/SUP], Jian Hur[SUP] 2 [/SUP], Jong Ho Lee[SUP] 3 [/SUP], Hong Nam Kim[SUP] #[/SUP][SUP] 4 [/SUP], Wonhwa Lee[SUP] #[/SUP][SUP] 5 [/SUP], June Hong Ahn[SUP] #[/SUP][SUP] 6 [/SUP]



Affiliations

• PMID: 32757497

Abstract

There are no proven therapeutics for Coronavirus disease 2019 (COVID-19) pneumonia outbreak. We observed and analyzed the clinical efficacy of the most used hydroxychloroquine (HCQ) for 30 days. In this study, administration of HCQ <5 days from diagnosis (odds ratio: 0.111, 95% confidence interval: 0.034 - 0.367, P = 0.001) was the only protective factor for prolonging of viral shedding in COVID-19 patients. Early administration of HCQ significantly ameliorates inflammatory cytokine secretion by eradicating COVID-19, at discharge. Our findings suggest that patients confirmed of COVID-19 infection should be administrated HCQ as soon as possible.

Keywords: Coronavirus Disease 2019; Early; Eradication; Hydroxychloroquine.